Argenx stock trades near record levels as oncology deal follows strong Q1 growth

Argenx stock remains elevated after solid Q1 2026 growth and a new oncology collaboration, with investors watching how rising operating costs balance against expanding antibody revenues.

Argenx stock is trading close to its recent record levels, reflecting investor confidence after strong growth in the first quarter of 2026 and a fresh oncology collaboration announced in 2024 that continues to shape the biotech group’s pipeline and revenue outlook.

Q1 2026 revenue climbs over thirty percent

According to the company’s first quarter 2026 results published on 7 May 2026 on its investor relations site, argenx SE (ISIN NL0010832176) reported total revenue of approximately $532 million in Q1 2026, up about thirty three percent from around $400 million in the first quarter of 2025.The Q1 2026 earnings release highlights continued uptake of the company’s lead FcRn-targeting antibody, as well as higher collaboration and milestone revenues.

In the same Q1 2026 report, operating income reached roughly $46 million compared with about $22 million in Q1 2025, indicating that profitability more than doubled even as argenx continued to invest heavily in clinical development and commercialization infrastructure.The detailed financial tables show that research and development expenses still represented a substantial proportion of the cost base, but growing product sales more than offset these investments.

Net income improves and cash position supports pipeline

The Q1 2026 statement also shows that net income attributable to shareholders rose to about $32 million, up from approximately $15 million a year earlier, giving argenx a clear year on year improvement in earnings despite ongoing spending on new indications and geographies.Management commentary emphasizes that this profitability improvement is primarily driven by higher gross margin on its lead antibody therapy combined with disciplined operating cost growth.

As of 31 March 2026, argenx reported a cash, cash equivalents and short term investments balance of roughly $3.0 billion, compared with about $2.5 billion at the end of March 2025.The balance sheet overview indicates that the company remains well funded to advance multiple clinical programs, including additional autoimmune and oncology indications that could expand its addressable market significantly over the coming years.

Oncology collaboration adds long term optionality

Beyond its core autoimmune franchise, argenx has been expanding into oncology through collaborations. In 2024, the company entered into a multi year oncology research and development partnership with a large pharmaceutical group focused on leveraging argenx’s antibody engineering platforms to create new cancer therapies, with the agreement including upfront, milestone and royalty components.Collaboration disclosures describe how this deal complements argenx’s internal pipeline by adding additional targets while sharing development risk.

According to the collaboration summary on the investor site, argenx recorded around $50 million of collaboration revenue in fiscal 2025 tied to oncology and other partnered programs, compared with approximately $30 million in 2024, reflecting an increase of about sixty seven percent year on year.The fiscal 2025 annual report suggests that while product sales remain the main driver of overall revenue, collaboration income provides diversification and validates the underlying technology platform for external partners.

Lead antibody drives majority of product sales

Argenx’s commercial success currently centers on its lead antibody therapy for generalized myasthenia gravis and other autoimmune conditions, which is marketed globally and forms the cornerstone of the company’s revenue base. In fiscal 2025, product sales of this antibody reached roughly $1.8 billion, up from about $1.3 billion in fiscal 2024, representing growth of around thirty eight percent year on year as argenx continued to gain market share and entered new geographies.The fiscal 2025 results presentation links this revenue expansion to more prescribers, longer treatment durations and broader label coverage.

The company’s data show that in fiscal 2025, this antibody accounted for more than eighty percent of total product revenue, underscoring its central role in argenx’s business model.Segment reporting tables illustrate how management is now investing in life cycle management and additional indications, aiming to reinforce the sustainability of this revenue stream even as competition in autoimmune therapies intensifies.

Stock supported by growing market capitalization

On Euronext Brussels, where argenx shares are primarily listed, the company’s market capitalization has expanded considerably alongside revenue growth. As of 31 March 2026, argenx’s market value stood at approximately EUR 28 billion, up from around EUR 22 billion a year earlier, according to data compiled from exchange statistics and the company’s investor reporting.Market capitalization overview shows that the biotech group now ranks among the larger healthcare names in the European equity universe.

This rising market capitalization means that argenx is more closely followed by international investors and index providers, improving secondary market liquidity and potentially lowering the company’s cost of capital over time.Shareholder information indicates that the investor base is distributed between US, European and other global institutions, many of which are attracted by the combination of growth momentum and a sizeable cash buffer.

Product focus on Vyvgart antibody franchise

Argenx’s lead commercial product is the FcRn-targeting antibody therapy marketed under the Vyvgart brand in multiple regions, which is indicated for generalized myasthenia gravis and is being studied in additional autoimmune diseases. The company’s fiscal 2025 reporting shows that Vyvgart generated approximately $1.8 billion in product sales that year, up from about $1.3 billion in 2024, confirming the thirty eight percent year on year growth referenced above.Brand level performance data attribute this increase to higher patient numbers, additional launches and continued adoption by neurologists and other specialists.

Argenx stock valuation reflects growth trajectory

Argenx stock’s valuation metrics, including its price to sales and price to earnings ratios, therefore reflect both the current scale of Vyvgart revenues and the optionality of new indications and oncology collaborations. As of 31 March 2026, the share price on Euronext Brussels was quoted near EUR 520, compared with around EUR 410 a year earlier, representing an increase of roughly twenty seven percent year on year in the context of strong earnings growth and a supportive broader biotech market.Historical price information suggests that the stock has traded in a 52 week range broadly between EUR 380 and EUR 540, putting the current level close to the top of that band.

Key data for Argenx

• Company: argenx SE
• ISIN: NL0010832176
• Ticker: EURONEXT: ARGX
• Trading venue: Euronext Brussels
• Price (as of 31 March 2026, 16:30 CET): 520.00 EUR
• Market capitalization: 28,000,000,000 EUR (as of 31 March 2026)
• Sector / Industry: Health Care / Biotechnology
• Index membership: STOXX Europe 600
• Next earnings date: 7 August 2026